A member of a key CDC advisory body told CNBC Friday morning that he was expecting a break in the US Johnson & JohnsonThe one-time coronavirus vaccine will eventually be repealed.
“I think we are ready to use this vaccine. We had to take an important pause to review this safety information to consider the risks. But I think there is a large amount of evidence that the Benefit far outweighs this risk, “said Dr. Wilbur Chen, professor in the University of Maryland School of Medicine.
Chen continued “Worldwide exchange” Hours before attending a Meet later Friday of the Agency’s Advisory Committee on Immunization Practices to discuss the rare but severe bleeding disorder that some women experienced after receiving the J&J shot.
In addition to the six patients who had rare but severe blood clotting problems after receiving the vaccine, the CDC is investigating two other possible cases: an Oregon woman who died and a Texas woman who was hospitalized. Of the original six women, one died and one became seriously ill. Approximately 8 million J&J vaccine doses have been given.
Concerns about the issue prompted the Centers for Disease Control and Prevention and the FDA to temporarily suspend use of the J&J vaccine in the US last week, but at the request of CNBCs Brian Sullivan whether he thinks Americans will eventually get the J&J vaccine, Chen said, “Yes.”
The Advisory Committee on Immunization Practices, known as ACIP, is an external panel of experts that makes recommendations to the CDC. It called a meeting on the J&J vaccine last week, however postponed a decision until this week. Ultimately, it is up to the CDC and the Food and Drug Administration what to do next.
Chen said ACIP now has better information about the blood clotting problems on which to base its vaccination instructions. “We’ll be able to get a good sample size. It may not be perfect, but we don’t have to be perfect to have actionable information,” said Chen, adding that the panel “will come up with a number of recommendations that I think everyone will be happy with. “
In a statement emailed to CNBC, CDC Director Dr. Rochelle Walensky, she hopes the health department receives a recommendation that considers the risk versus reward of using the Johnson & Johnson vaccine based on the new case data and the risk-benefit analysis CDC conducted last week. “
“I really appreciate the complex issue before the committee and look forward to hearing from you. I also appreciate the importance of working with the FDA to act quickly as soon as we hear about ACIP,” added Walensky .
Given the urgency of the Coronavirus pandemicSome people have criticized the decision to discontinue J&J Covid’s vaccine – which only needs one dose for full immunity protection – while the clot screening was going on.
“The risk is very, very small, but until we could fully take into account this information, we haven’t been able to contextualize this for the rest of the medical community, including the public,” he said. “We only took a 10-day break. Hopefully this will not be harmful in the long term, but of course we want to instill confidence in the system for collecting safety information.”